Pro Medicus Limited Signs Five-year RIS Deal with Primary Health Care Limited

14 March 2017; Company Announcement - Primary Health Feb 2017 - Acrobat pdf 180k Highlights Five-year deal with Primary Health Care Limited, one of the largest diagnostic imaging networks in Australia PME to provide Visage RIS to Primary Health Care’s 141 diagnostic imaging sites Will deliver 11% uplift to PME’s FY16 revenue each year for 5 years Transaction-based agreement with potential upside Leading healthcare imaging company Pro Medicus Limited [ASX: PME] today announced it has signed a five-year agreement with Healthcare Imaging Services, the diagnostic imaging division of Primary Health Care Limited [ASX:PRY], one of Australia's leading ASX-listed healthcare companies. The agreement will see Pro Medicus install its Visage RIS (radiology information system) throughout the Healthcare Imaging Services network. The major functions of the RIS software includes patient scheduling, billing and back office practice management functions. Healthcare Imaging Services is one of Australia’s largest diagnostic imaging networks. It comprises 141 diagnostic imaging sites throughout Australia, with operations in New South Wales, ACT, Victoria, South Australia, West Australia and Queensland. The five-year transaction-based agreement is expected to deliver an uplift equivalent to 11% of the Company’s FY16 revenue for each year of the contract. Dr Sam Hupert, CEO of Pro Medicus said, “This is one of the largest RIS deals in Australia, so it is very significant for us. With this contract we will regain our dominant position in the Australian RIS market.” Chief Executive of Healthcare Imaging Services, Dean Lewsam, said: “We undertook an extensive evaluation process before deciding on the Visage RIS from Pro Medicus." “Visage RIS has the functionality and scalability that a large geographically diverse group such as ours requires. We expect a national system will help deliver significant efficiencies across our business.” Implementation is

Pro Medicus Limited Interim Results

17 February 2017  |  Company Announcement Pro Medicus Limited Half Year 2016-17 Results - Acrobat pdf 463k Highlights: After-tax profit of $4.80 million – up 63.1% Revenue of $15.20 million – up 6.4% Underlying profit after tax - $4.08 million – up 44.7% Cash reserves $20.28 million – up $3.17 million in the six-month period Interim dividend of 1.5c per share unfranked Leading health imaging company Pro Medicus Limited [ASX: PME] today announced a first-half after-tax profit of $4.80 million for the six months to 31 December 2016 – 63.1% higher than for the previous corresponding period. Revenue for the six months was $15.20 million – a 6.4% increase on the previous corresponding period. Profit after tax from underlying operations for the half was $4.08 million compared to $2.82 million from the previous corresponding period, an increase of 44.7%. The company's cash reserves were $20.28 million at the end of the period, an increase of $3.17 million for the six-month period. The company remains debt-free and announced an unfranked interim dividend of 1.5c per share. Pro Medicus CEO, Dr Sam Hupert said, “During the period we continued to make significant inroads into the North America market. In July we signed an $18 million six-year contract with Mayo Clinic, one the world’s most recognised health systems, whilst operationally we were extremely busy installing a large number of new Visage 7 sites. Pleasingly, all of these implementations were on, or ahead of schedule.” “Transaction based revenue from our US operation grew strongly as more facilities were brought on line whilst at the same time expenses, as a percentage of revenue, were down. We see these trends continuing in the second half.” The company is looking to build on its presence in

Pro Medicus Limited Full-Year Results

19 August 2016  |  Company Announcement Pro Medicus 2016 Full Year Results - Acrobat pdf 189k Highlights: After-tax profit $6.37 million – up 98% Underlying after-tax profit up 212% Revenue increased to $27.58 million – up 57% Cash reserves $17.1 million - up 32% Final dividend of 1.5c per share unfranked; total for year 3c per share Rapidly expanding footprint in North American market Leading health imaging company Pro Medicus Limited [ASX: PME] today announced a full-year after-tax profit of $6.37 million for the 12 months to 30 June 2016 – a 98% increase on the previous corresponding period. Revenue for the year grew by 57% to $27.58 million. The company's cash reserves grew to $17.1 million an increase of 32%. The company remains debt-free. Directors announced an unfranked final dividend of 1.5c per share, making a total dividend for the year of 3c per share. During the period the company made announcements for contracts with a minimum value of A$60 million including: Allegheny Health Network, USA - Sept 2015, A$11 million five-year contract. German Government Hospital - Nov 2015, A$3 million five-year contract. Mercy Health System - April 2016, A$21 million seven-year contract with the seventh largest Catholic health care system in the USA. Franciscan Missionaries of Our Lady Health System - April 2016, A$7 million, seven-year contract with the largest health system in the US state of Louisiana. Mayo Clinic - July 2016, A$18 million, six-year contract with Mayo Clinic, USA. Key drivers of the company’s profit increase for the year were the significant increase in the performance of the North American operations, supplemented by a capital sale in Europe and a modest increase in Australian sales. As the Group’s costs are relatively fixed, this increase

Pro Medicus Signs Key US Contract

4 July 2016; Company Announcement Pro Medicus Signs Mayo Clinic - Acrobat pdf 123k Key Points PME signs 6 year deal with Mayo Clinic in the US Visage 7 to be implemented enterprise-wide throughout Mayo Clinic’s Radiology departments Estimated value to PME in excess of AUD $18 million Transaction-based model with potential upside Third major US deal in 4 months Recent deals reposition PME in US market Leading health imaging company Pro Medicus Limited [ASX: PME] today announced its wholly owned US subsidiary, Visage Imaging, Inc., has signed an AUD $18 million, six-year contract with Mayo Clinic. The contract, based on a transaction licensing model, will see Pro Medicus’ Visage 7 technology implemented across Mayo Clinic’s Radiology practices. Project planning has begun with the first sites scheduled to move into production in the second quarter of FY2017 with the remaining sites rolling out over an 18 month period with project completion set for the fourth quarter of FY2018. “This is a very significant contract for us and further validates our belief that Visage 7 is uniquely positioned to cater for the needs of the most sophisticated and demanding clinical environments,” said Dr Sam Hupert, Pro Medicus CEO. “It has the speed and functionality to meet the requirements of a large and diverse group of high-end clinical users as well as the scalability to handle the huge data volumes that a medical enterprise of this size generates”. Dr Hupert continued, “This is the third major deal we have signed in the past few months following our recent Mercy and FMOLHS announcements, and further cements our growing footprint in the North American market. With this deal we have reached another major milestone in terms of market acceptance and we look to build on this

PME Signs A$7M deal with US-based Franciscan Missionaries of Our Lady Health System

27 April 2016; Company Announcement FMOLHS April 2016 - Acrobat pdf 163k Key Points Franciscan Missionaries of Our Lady Health System (FMOLHS) to use Pro Medicus’ Visage 7 technology for primary diagnosis and enterprise distribution of medical images Seven-year deal with base value to PME of A$7M Transaction-based model with potential upside Second deal as part of the ROi master purchasing agreement Leading health imaging company Pro Medicus Limited [ASX: PME] today announced its wholly owned US subsidiary Visage Imaging, Inc has signed an A$7 million, 7-year contract with the Franciscan Missionaries of Our Lady Health System (“FMOLHS”), the largest health system in the U.S. state of Louisiana. The contract, based on a transaction licensing model, will see Pro Medicus’ Visage 7 technology implemented at FMOLHS’s five acute care and specialty hospitals. Once fully implemented, Visage 7 will be a key component of FMOLHS’s enterprise viewing platform and will be used for primary diagnoses, enterprise distribution and access to radiology images by over 2,000 physicians via the system’s new electronic health record (EHR). FMOLHS is also a shareholder of ROi, a leading US health care supply-chain organization with this the second deal completed under the Visage/ROi agreement announced in April of this year. Planning for the project is scheduled to begin in the first quarter of FY2017, with the first phase of the implementation to commence in the 2nd half of FY2017 to coincide with the rollout of FMOLHS’s EHR. It is estimated the project will take 12 months to complete. The FMOHLS sale builds on the four large enterprise system deals Pro Medicus has won in the previous 12 months. These include the University of Florida Health in April 2015, Allegheny Health Network in September 2015, a

PME Appoints Anthony Glenning as Director

20 April 2016; PME Appoints Anthony Glenning as Director - Acrobat pdf 184k Leading health imaging company Pro Medicus Limited [ASX: PME] today announced the appointment of Mr Anthony Glenning as a Non- Executive Director, effective 1 May 2016. At last year’s AGM the Chairman indicated that the Board intended appointing another Non-Executive Director with complementary skills. With the assistance of an Executive Search firm the Board conducted an extensive search to identify suitable candidates. Today’s announcement is the culmination of that process. Mr Glenning has considerable experience in software development and has spent approximately 14 years living and working in Silicon Valley in California USA. He has a background in engineering and holds a Master’s degree in Electrical Engineering from Stanford University, along with Bachelors’ degrees in Computer Science and Electrical Engineering from the University of Melbourne. Mr Glenning was the founder and CEO of Tonic Systems, a company that developed software for creating and managing online presentations, which was sold to Google in 2007. The software was integrated into Google’s online corporate software – Google Docs, with Anthony working for Google at the Googleplex headquarters in the two years following the acquisition. Mr Glenning was also a founding non- executive director of Cameron Systems, a company providing software solutions to financial businesses until it was acquired by Orc Software in 2006. Mr Glenning joined investment firm Starfish Ventures in 2010 where he is currently an Investment Director and sits on the boards of a number of Starfish portfolio companies. The Board welcomes Anthony to the company and looks forward to working with him.

Dr Sam Hupert | CEO on Mercy Contract

4 April 2016  |   PME CEO on Mercy Contract - Acrobat pdf 238k Open Briefing interviewed Pro Medicus CEO, Dr Sam Hupert, discussing the latest contract with Mercy.        

Pro Medicus Signs A$21M Deal with US-based Mercy Health

4 April 2016; Company Announcement Pro Medicus Signs Mercy - Acrobat pdf 169k Key Points Mercy Health System to use Pro Medicus’ Visage 7 technology for primary diagnosis and distribution of medical images Seven-year deal with base value to PME in excess of A$21M Mercy has 46 acute care and specialty hospitals spanning four US states Transaction-based model with potential upside First deal as part of the ROi Master purchasing agreement Leading health imaging company Pro Medicus Limited [ASX: PME] today announced its wholly owned US subsidiary Visage Imaging, Inc has signed an A$21 million, 7-year contract with Mercy Health System (‘Mercy’), the seventh largest Catholic health care system in the USA. The contract, based on a transaction licensing model, will see Pro Medicus’ Visage 7 technology implemented across Mercy’s 46 acute care and specialty hospitals, supporting more than 2,000 physicians and 40,000 employees across the mid-west states of Missouri, Arkansas, Oklahoma and Kansas. Once fully implemented, Visage 7 will be a key component of Mercy’s enterprise viewing platform and will be used for primary diagnoses, clinical distribution and access to radiology images via Mercy’s electronic health record (EHR). Mercy is also the founder and major shareholder of ROi, a leading US health care supply-chain organization. As part of this deal Visage Imaging has entered into a master purchasing agreement with ROi. The deal with Mercy will be the first completed under this new ROi agreement. This paves the way for all ROi members to benefit from this group-wide purchasing agreement. Planning for the project is scheduled to begin in the last quarter of FY2016, with the first phase of the implementation to commence in the first quarter of FY2017. It is estimated the project will take between

Go to Top